Davide Pastorelli

Davide Pastorelli

Auto-generated profile, based on publicly available information

Davide Pastorelli

Rare Tumors Unit, Veneto Institute of Oncology IOV - IRCCS, Via Gattamelata 64, 35128 Padua (PD), Italy; Department of Oncology, S. Maria del Prato Hospital, Via Bagnols sur Ceze 3, 3203 Feltre (BL), Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CSCaterina Solda
Caterina Solda
CSCosimo Sperti
Cosimo Sperti
BRBardini Romeo
Bardini Romeo
GDGianfranco Da Dalt
Gianfranco Da Dalt
MGMassimo Gion
Massimo Gion
DPDavide Pastorelli
Davide Pastorelli
E15696 Background: GEM still represents one of the mostly adopted treatments for PC. Combination treatments provided some improvement in response rate (RR) and progression free survival (PFS), although almost invariably associated to increased toxicity. Aiming to find a complementary therapy to GEM in advanced PC, we tested a preparation of curcumin complexed with phospholipids (Meriva) to increase bioavailability. Curcumin has antinflammatory, antioxidant and potential antitumor properties, seemingly, descending from the activation of nuclear factor Nrf2 and inhibition of NFkB. From this pattern of nutraceutical effects of Curcumin, Meriva emerges as a good candidate for complementary therapy, while also improving quality of life (QoL). Methods: This was a single centre, single arm prospective phase II trial. Inclusion criteria were: previously untreated patients with histologically confirmed metastatic or locally advanced PC, ECOG performance status (PS) of 0-2, adequate organ function and written informed consent. Patients received GEM (1,000 mg/mq in 100 minutes on day 1,8,15 every 28 days) and Meriva (2,000 mg/die, continuously) until progression, unacceptable toxicities or refusal. Primary endpoint was RR (according to RECIST 1.1), secondary endpoints were PFS, OS, tolerability and finally QoL. Serum samples collection for inflammatory biomarkers was also performed. Results: Between October 2012 and February 2015 a total of 57 consecutive patients were enrolled. Forty-four patients (15 females and 29 males; 13 locally advanced and 31 metastatic) were suitable for primary endpoint evaluation. Median age was 66 years (range 42-87); all patients except two had ECOG PS 0-1. The median number of treatment cycle was 4.5 (range 2-14). The overall RR was 27,3% (all partial responses), stable disease was reported in 34% of cases with a disease control rate of 61.3%. Grade 3/4 toxicity was observed as neutropenia (7.9%) and anemia (3%). Conclusions: Meriva as complementary therapy to GEM was safe and translate in good disease control rate in first line therapy of advanced PC. Biomarker screening is ongoing to identify patients who get the best benefit from this combination.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SDSimona D'Ippolito
Simona D'Ippolito
EAEttore Ambrosini
Ettore Ambrosini
MSMalihe Shams
Malihe Shams
GCGiuseppe Calì
Giuseppe Calì
DPDavide Pastorelli
Davide Pastorelli
10070 Background: Convergent findings indicate the need of broadening the vision of cancer beyond known prognostic factors, as many variables of different nature equally affect the course of disease. Loneliness has been found to be associated with various health outcomes, but its relationship with cancer remains unclear. Here we aimed to investigate the specific effect of loneliness and other demographic, psychological, and clinical variables on cancer mortality and to validate the Italian UCLA Loneliness Scale in cancer patients. Methods: This descriptive and correlational study was conducted at the Veneto Institute of Oncology in Padua. 400 patients undergoing chemotherapy from 01/2014 to 06/2015 were enrolled. The sample was stratified by sex and age (4 groups, 40-80 y). We collected demographic, clinical (site and stage of cancer, type of chemotherapy, death date), and psychosocial [self-esteem (RSE), perceived social support (MSPSS), social interaction anxiety (SIAS), personality (EPQR), and depression (BDI)] data. Results: GLM analyses: loneliness was higher in women than men (F(1,398) = 7.5, p = .006) and it linearly increased with age (F(1,398) = 10.9, p = .001). Loneliness was also influenced by marital status (F(3,396) = 2.9, p = .037), cohabitant offspring (F(1,398) = 7, p = .008), and educational level (F(3,396) = 4.7, p = .003), but not by clinical variables (all ps > .05). Correlation analyses: loneliness was inversely related to RSE (r = -.51), MSPSS (r = -.52), and extroversion (r = -.32), and directly related to SIAS (r = .46), neuroticism (r = .43), and BDI (r = .44). More importantly, a hierarchical binomial logistic regression revealed that patients’ mortality was reliably predicted by gender, stage of cancer at diagnosis, time from diagnosis to UCLA collection, BDI, and UCLA (HL χ2(8) = 3.53, p = .90). In particular, high BDI predicted higher mortality (Wald = 11.6, p < .001); surprisingly, after controlling for BDI and other effects, high loneliness predicted lower mortality (Wald = 7, p = .008). Conclusions: Our results replicate prior research and reveal a surprising association between loneliness and mortality risk after partialling out the impact of, especially, depression. This suggests the role of loneliness on cancer course as an important health concern.

1 January 2003
Verified
Journal Article
Closed access
CSCosimo Sperti
Cosimo Sperti
Claudio PasqualiClaudio Pasquali
Claudio Pasquali
DPDavide Pastorelli
Davide Pastorelli
AFAndrea Ferronato
Andrea Ferronato
GDGiandomenico Decet
Giandomenico Decet
SPSergio Pedrazzoli
Sergio Pedrazzoli